FAIR-PARK II

Conservative Iron Chelation as a Disease-Modifying Strategy in Parkinson's Disease

This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.

Population: adult | Intervention type: therapeutic medicinal product